Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease

[Article in English, Chinese]
Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease et al. Zhongguo Dang Dai Er Ke Za Zhi. 2021.

Abstract
in English, Chinese

Kawasaki disease is an acute, self-limited vascuitis that mainly occurs in children under 5 years of age. Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications. However, there has been no consensus or clinical guidelines for the application of IVIG in children with Kawasaki disease till now. This consensus is developed based on the current research progress on the application of IVIG in children with Kawasaki disease in China and overseas, with reference to the diagnosis and treatment guidelines for Kawasaki disease in China and overseas, and the opinions of experts. This consensus provides recommendations on the clinical application strategy of IVIG in children with Kawasaki disease and the prevention and treatment of its adverse reactions. Citation.

川崎病是一种好发于5岁以下儿童的急性自限性血管炎性疾病。静脉输注免疫球蛋白（intravenous immunoglobulin，IVIG）已经成为一种有效的治疗方案，可以有效减少心血管并发症的发生率，但目前国内外尚无儿童川崎病IVIG应用共识或临床指南。该共识是基于目前国内外关于儿童川崎病中IVIG应用的研究进展，同时参考国内外川崎病的诊疗指南，并经过制定专家充分讨论而形成。该共识对IVIG在儿童川崎病中的临床应用策略及其不良反应的防治提出了具体建议。 引用格式.

Keywords: Child; Expert consensus; Intravenous immunoglobulin; Kawasaki disease; Self-limited vasculitis.

PubMed Disclaimer

Conflict of interest statement

共识由小组内成员自行完成，未接受赞助，小组内成员不存在任何利益冲突。

References

    1. Ae R, Makino N, Kosami K, et al. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017-2018[J]. J Pediatr, 2020, 225: 23-29.e2. DOI: 10.1016/j.jpeds.2020.05.034. - DOI - PubMed
    1. Du ZD, Zhao D, Du JB, et al. Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004[J]. Pediatr Infect Dis J, 2007, 26(5): 449-451. DOI: 10.1097/01.inf.0000261196.79223.18. - DOI - PubMed
    1. Barrios Tascón A, Centeno Malfaz F, Rojo Sombrero H, et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease[J]. An Pediatr (Barc), 2018, 89(3): 188.e1-188.e22. DOI: 10.1016/j.anpedi.2018.04.003. - DOI - PubMed
    1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. DOI: 10.1161/CIR.0000000000000484. - DOI - PubMed
    1. 中国医师协会儿科医师分会风湿免疫学组, 中国儿童免疫与健康联盟, 《中国实用儿科杂志》编辑委员会 . 儿童风湿性疾病相关巨噬细胞活化综合征诊断与治疗专家共识之一: 总论篇[J]. 中国实用儿科杂志, 2020, 35(11): 825-831. DOI: 10.19538/j.ek2020110601. - DOI

Substances